Patient Advocate University

Welcome to Patient Advocate University, a website designed to provide you with the informational resources you need to support your patients throughout their treatment journey once XYWAV is prescribed. We are here to support you along the way to help your patients start on XYWAV.

You will find

  • The 5 steps to getting appropriate patients started on XYWAV and providing ongoing support throughout their treatment journey
  • Informative videos for each of the 5 steps that provide guidance, tips, and best practices
  • A downloadable checklist to track your patient’s progress during the onboarding process
  • Resources and support for every step of the treatment journey

Help your patients get started on XYWAV in 5 steps

Because of the risks of CNS depression and abuse and misuse, XYWAV is only available through a restricted program under the XYWAV and XYREM Risk Evaluation and Mitigation Strategy (REMS).1,a Getting your patient started on XYWAV in a timely manner starts with required enrollment by you and your patient in the XYWAV and XYREM REMS.b The required forms (see below in the “Resources” section) must be submitted to the Certified Pharmacy to complete the enrollment process. All 3 forms can be completed online, via fax, or by mail. The enrollment forms only need to be submitted one time.

To unlock JazzCares® access and affordability programs,c it is recommended that patients enroll in JazzCares by completing the online JazzCares Patient Authorization Form (see below in the “Resources” section).

aBecause of the serious risks associated with XYWAV, the Food and Drug Administration has required a special program called the XYWAV and XYREM REMS. The purpose of the XYWAV and XYREM REMS is to make sure that the benefits of XYWAV outweigh the risks.1,2
bXYWAV is dispensed only by the central pharmacy that is specially certified and will only be dispensed and shipped to patients who are enrolled in the XYWAV and XYREM REMS with documentation of safe use.1
cNot all patients are eligible for JazzCares access and affordability programs.

 

XYWAV and XYREM REMS Prescriber Enrollment Form

If you have questions, call 1-866-997-3688.

XYWAV and XYREM REMS Patient Enrollment Form

If you have questions, call 1-866-997-3688.

XYWAV Prescription Form

If you have questions, call 1-866-997-3688.

JazzCares Patient Authorization Form

For more information, call 1-833-533-JAZZ (5299).

Patient Support App

Available for download.

aPrescribers can certify in the XYWAV and XYREM REMS online by scrolling down and clicking “Prescriber Enrollment” and then scrolling down to “Option 2.” Prescribers can enroll patients online by scrolling down and clicking “Patient Enrollment” and then scrolling down to “Option 2.”
bPrescribers can complete electronic prescriptions by selecting the "ePrescribe Now" button, located in the "Prescribe XYWAV or XYREM" section of the XYWAV and XYREM REMS website.

Once enrollment in XYWAV and XYREM REMS is complete and the prescription has been submitted, your patients will receive 2 calls: 1 from their JazzCares Nurse Case Manager and the second from a pharmacist at the Certified Pharmacy. The purpose of these calls is to discuss insurance information, explain the getting-started process, provide counseling, and discuss treatment.

Advise your patients to add these phone numbers to their contacts: 1-888-376-3917 (JazzCares Nurse Case Manager) and 1-866-997-3688 (Certified Pharmacy).

 

XYWAV Patient Resources – Cataplexy and/or EDS With Narcolepsy

XYWAV Patient Resources – Idiopathic Hypersomnia

A dedicated JazzCares team provides support to your patients and their caregivers throughout the reimbursement and insurance coverage process. This team works with you to verify each patient’s insurance coverage and offers multiple financial assistance options for eligible patients.a

aInsurance coverage and plans may vary. The JazzCares program at Jazz Pharmaceuticals, Inc. provides general information only and is not a guarantee of any coverage or reimbursement outcome. All treatment decisions rest solely with the treating physician or qualified healthcare professional.

 

Guide to Completing a Prior Authorization – Cataplexy and/or EDS in Narcolepsy

Guide to Completing a Prior Authorization – Idiopathic Hypersomnia

ICD-10-CM and NDC Codes Flashcard

JazzCares Financial Assistance Programs Flashcard

ICD-10-CM=International Classification of Diseases, Tenth Edition, Clinical Modification; NDC=National Drug Code.

Prior to your patient’s first shipment, a pharmacist at the Certified Pharmacy will call to offer counseling and provide delivery requirements. Once your patient receives their first shipment of XYWAV, their JazzCares Nurse Case Manager will call to review storage details and conduct a non-adherence risk assessment. Next, a JazzCares Nurse Educator will schedule a teach session with your patient and provide ongoing support.

 

A dedicated team provides support to you, your patients, and their caregivers after your patient has received XYWAV:

  • Pharmacist support through the Certified Pharmacy
  • Nursing support team, including a JazzCares Nurse Case Manager and JazzCares Nurse Educator
  • Reimbursement specialist
  • Jazz Access and Reimbursement Manager

In addition, personalized resources are available for your patients, including online refill reminders and scheduling via text and email, the XYWAV Mentor Program, and the myWAV app.

 

Reauthorization of XYWAV Flashcard

XYWAV Mentor Program

For more information, call 1-866-539-3946.

Download a checklist to get your patients started on XYWAV in 5 steps

Additional resources

Guidance for JazzCares Patient Authorization Form

Letter of Medical Necessity Template – Cataplexy and/or EDS in Narcolepsy

Letter of Medical Necessity Template – Idiopathic Hypersomnia

CNS=central nervous system; EDS=excessive daytime sleepiness.

References: 1. XYWAV [package insert]. Palo Alto, CA: Jazz Pharmaceuticals, Inc. 2. Risk Evaluation and Mitigation Strategies. REMS. Food and Drug Administration website. https://www.fda.gov/drugs/drug-safety-and-availability/risk-evaluation-and-mitigation-strategies-rems. Updated May 16, 2023. Accessed November 17, 2023.